Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.
Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.
Israeli drug manufacturer Teva Pharmaceuticals is suing India-based Cipla to block the launch of generic Qvar asthma inhalers.
In a victory for Bristol-Myers Squibb and Pfizer, a US federal judge has affirmed patents covering blood-thinner Eliquis.
Buyers of AbbVie’s arthritis treatment Humira have appealed against an Illinois judge’s decision to dismiss their class action antitrust suit to the US Court of Appeals for the Seventh Circuit.
A US federal appeals court has refused to block California’s ban on pay-for-delay deals in the generic drugs industry.
A subsidiary of India’s Sun Pharma has agreed to pay more than $200 million to settle charges related to a generics price-fixing investigation.
The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
The Federal Court of Australia has upheld a patent victory for Indian generic manufacturer Sun Pharma over Mylan in a dispute over cholesterol drug fenofibrate.
Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.